Related Experiment Video
Updated: Mar 27, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell
A Ouerdani1, H Struemper2, A B Suttle2
1Inria, project team NuMed Ecole Normale Supérieure de Lyon, Lyon France.
Abstract:
The objective was to leverage tumor size data from preclinical experiments to propose a model of tumor growth and angiogenesis inhibition for the analysis of pazopanib efficacy in renal cell carcinoma (RCC) patients. We analyzed tumor data in mice with RCC CAKI-2 cell line treated with pazopanib. Clinical tumor size data obtained in a subset of patients with RCC were also analyzed. A model accounting for the processes of tumor growth, angiogenesis, and drug effect was developed. The final tumor model was composed of two variables: the tumor and its vasculature. Our results show that, both in mice and in humans, pazopanib exhibits a dual mechanism of action, and parameter estimation values highlight the inherent difference between mice and humans on the time scale of tumor size response. We developed a semimechanistic tumor growth inhibition model that takes into account tumor angiogenesis in order to describe the effects of pazopanib in mice. Analyzing rich preclinical data with a semimechanistic model may be a relevant approach to facilitate the description of sparse clinical longitudinal tumor size data and to provide insights for the understanding of the drug mechanisms of action in patients.
Insights
Pazopanib demonstrated a dual mechanism of action in inhibiting renal cell carcinoma (RCC) tumor growth and angiogenesis in both mice and humans. Preclinical data modeling provided insights into human patient responses to pazopanib therapy.
Area of Science:
- Oncology
- Pharmacology
- Mathematical Biology
Background:
- Renal cell carcinoma (RCC) is a significant health concern.
- Understanding pazopanib's mechanism of action is crucial for effective treatment.
- Tumor growth and angiogenesis are key factors in RCC progression.
Purpose of the Study:
- To develop a mathematical model for tumor growth and angiogenesis inhibition.
- To analyze pazopanib efficacy in preclinical models and RCC patients.
- To elucidate the dual mechanism of action of pazopanib.
Main Methods:
- Utilized tumor size data from preclinical experiments with RCC CAKI-2 cell line in mice.
- Analyzed clinical tumor size data from a subset of RCC patients.
- Developed a semimechanistic model incorporating tumor growth, angiogenesis, and drug effects.
Main Results:
- Pazopanib exhibits a dual mechanism of action in both mice and humans.
- Parameter estimation revealed differences in the time scale of tumor response between mice and humans.
- The developed model effectively described pazopanib's effects on tumor angiogenesis.
Conclusions:
- Semimechanistic modeling of preclinical data can inform the analysis of sparse clinical data.
- The study provides insights into pazopanib's mechanism of action in RCC.
- Modeling facilitates a deeper understanding of drug efficacy and inter-species differences in response.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
